The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Cancer Policy

Bhattacharya cancels NIH all-hands meeting

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
BYLINEDOWNLOAD PDFTABLE OF CONTENTS

In an interview with Science, NIH Director Jay Bhattacharya said that his time at the NIH has been a “tough period”—especially for him. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Byline
Jacquelyn Cobb
Associate Editor
Table of Contents

YOU MAY BE INTERESTED IN

In Brief

Dana-Farber/Harvard Cancer Center awarded $12M NIH SPORE grant to advance breast cancer research

From left to right: Geoffrey Shapiro, Leif Ellisen and Nancy Lin. Sitting below them is Kornelia Polyak.The Dana-Farber/Harvard Cancer Center,  a cancer research consortium comprised of five of Boston’s academic medical centers, including Dana-Farber Cancer Institute and Massachusetts General Hospital, has been awarded an NCI grant to continue its Specialized Program of Research Excellence in Breast Cancer.

AACR Cancer Progress Report makes the case for federal investment in cancer research

As NCI and NIH funding is being deliberated in Congress, this year’s 2025 AACR Cancer Progress Report had an unequivocal message: With 20 new anticancer therapeutics, new uses for eight previously approved anticancer therapeutics, two new early detection tools, and several AI-powered diagnostics approved over the span of just one year, cancer research funding yields a good return on investment. 
By Sara Willa Ernst
Byline
Jacquelyn Cobb
Associate Editor
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account